摘要
目的观察僵龙通络平哮方对支气管哮喘急性发作期T淋巴细胞亚群和肺功能的影响。方法 96例急性发作期哮喘患者随机分为对照组和治疗组各48例,对照组予以西医常规治疗,治疗组在西医常规治疗基础上予以僵龙通络平哮方加减治疗。两组疗程均为14d。结果治疗组总有效率为93.75%,高于对照组的87.50%(P<0.05);两组治疗后用力肺活量(FVC)、第1秒用力呼气容积(FEV1.0)、1秒率(FEV1.0/FVC)、峰流速(PEF)等较治疗前均升高,治疗组改善程度优于对照组(P<0.05或P<0.01);两组治疗后CD4+、血清IgE和呼出气一氧化氮(FeNO)水平均较治疗前降低,治疗组降低更明显(P<0.05或P<0.01);治疗组CD4+/CD8+较治疗前降低(P<0.01),而对照组较治疗前降低不明显;两组治疗后CD8+均有升高,治疗组升高更明显(P<0.05)。结论僵龙通络平哮方能明显缓解急性发作期支气管哮喘患者的症状、体征,改善肺功能,调节免疫功能,抑制气道炎症。
Objective To observe the effect of Jianglong Tongluo Pingxiao decoction on T lymphocyte subsets and pulmonary function in patients with acute exacerbation of bronchial asthma. Methods 96 cases of patients with acute exacerbation of asthma were randomly divided into control group and treatment group, 48 cases in each group. Control group was given conventional western medical treatment. Treatment group was treated with Jianglong Tongluo Pingxiao decoction on the basis of control group. Both groups were treated for 14 d. Results The total effective rate of treatment group was 93.75%, which was higher than 87.50% of control group(P<0.05);FVC,FEV1.0,FEV1.0/FVC,PEF were all increased after treatment in both groups, and the improvement in treatment group was more obvious than that in control group CP<0.05 or P<0.01) After treatment, the levels of CD4+, serum IgE and FeNO in the two groups were lower than those before treatment, and the decrease in treatment group was more obvious(P<0.05 or P<0.01). CD4+/CD8+ in treatment group was lower than those before treatment(P<0.01), but that of control group was not significantly lower than that before treatment;CD8+ in both groups were increased after treatment, treatment group increased more significantly(P<0.05). Conclusion Jianglong Tongluo Pingxiao decoction can obviously relieve symptoms and signs of patients with acute exacerbation of bronchial asthma, improve lung function, regulate immune function and inhibit airway inflammation.
作者
杨宏志
杨俊姝
冯毅
郭光辉
王鹏
YANG Hongzhi;YANG Junshu;FENG Yi;GUO Guanghui;WANG Peng(Hubei Provincial Hospital of Traditional Chinese Medicine,Wuhan 430061;Hubei Academy of Traditional Chinese Medicine,Wuhan 430074;The First Clinical College,Hubei University of Chinese Medicine,Wuhan 430061)
出处
《湖北中医药大学学报》
2019年第1期31-34,共4页
Journal of Hubei University of Chinese Medicine
基金
国家中医临床研究基地课题(湖北)科研专项(项目编号:JDZX2014Y08)
关键词
支气管哮喘
急性发作期
僵龙通络平哮方
络病
bronchial asthma
acute attack
Jianglong Tongluo Pingxiao decoction
collateral disease